Spirit Pharmaceutical
Spirit Pharmaceuticals is meeting the challenge of providing an alternative supply point for a range of specialist pharmaceuticals.
> News
1.06.10 - PBS listing for ClovixSpirit’s generic clopidogrel Clovix is PBS listed. Clovix is interchangeable with Sanofis’ Plavix. Clovix is sold and distributed by Sigma Pharmaceuticals (1300 132 293)
22.05.10 - Appointment - IP Manager and Health Economics DirectorSpirit Pharmaceuticals appoints Ms Helen Wray as IP Manager and Health Economics Director
2.04.10 - Appointment - R&D Technical ManagerSpirit Pharmaceuticals appoints Ms Tandy Houseman R&D Technical Manager.
25.01.10 - Spirit Pharmaceuticals launches SozolSpirit Pharmaceuticals launches its pantoprazole tablet Sozol, which is interchangeable with Nycomed’s Somac. Sozol is being sold and distributed by Sigma Pharmaceuticals (1300 132 293)
> Products
Spirit Pharmaceuticals currently has a number of products approved for market including Azithromycin and Simvastatin tablets.
A number of other products are currently lodged with the TGA for approval. Please contact Managing Director to discuss further.
> About us
Spirit Pharmaceuticals specialise in the commercialisation of prescription pharmaceuticals for the Australian retail and hospital markets.
Spirit is focussed on products that require specialised support to gain TGA approval. This support may be regulatory or clinical.
The Spirit personnel have considerable experience in the area of injectable hospital products and are actively developing a portfolio in this area.
In 2004 Spirit received its first TGA approval, this has been followed by a growing range of products that have been approved, lodged or are under investigation